News
EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...
One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy—and an aggressive type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback